

## A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- diagnosis of Stage IV non-squamous NSCLC not amenable to curative surgery or radiation - tumors with STK11 or KEAP1 or KRAS mutations - no prior chemotherapy or immunotherapy for metastatic cancer - unable to do strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - men and women of child bearing age and their partners must use an acceptable method of contraception - body weight of > 30 kg (66 pounds) - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Inclusion criteria

---

#### Exclusion Criteria:

- evidence of acute or uncontrolled diseases or history of allogeneic organ transplant - active or prior autoimmune or inflammatory disorders - women who are pregnant (confirmed with positive pregnancy test) or breastfeeding, or who are planning to become pregnant - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Exclusion criteria

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

Non Small Cell Lung Cancer, NSCLC

### More Information

**Description:** In this trial, researchers want to learn more about how well durvalumab plus tremelimumab with chemotherapy works in people with metastatic NSCLC and genetic mutations that can cause the cancer to be less responsive to treatment. This trial is planned to have 280 participants. These participants will be randomly (by chance) divided into one of two groups. One group will receive durvalumab plus tremelimumab with standard of care chemotherapy and one group will receive pembrolizumab with standard of care chemotherapy.

**Study Contact:** Kristen Nelson - [knelso65@fairview.org](mailto:knelso65@fairview.org)

**Principal Investigator:** James Shanks

**Phase:** PHASE3

**IRB Number:** MMCORC083

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.